SCHEMBL15976000

SCHEMBL15976000

COC(=O)c1cc(Br)nc(-c2ccccc2)c1N=[N+]=[N-]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 1/20 0.41
ALDH1A1 P00352 4/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.39
PLA2G2A P14555 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HPGD P15428 2/20 0.37
GAA P10253 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM4E B2RXH2 1/20 0.37
PTGS1 P23219 1/20 0.37
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
USP2 O75604 1/20 0.36
LMNA P02545 1/20 0.36
AXL P30530 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15976016 0.88 MAPT (0.43) ALDH1A1MAPTSMN1; SMN2PLA2G2AL3MBTL1
SCHEMBL15976013 0.87 MCL1 (0.41) SMN1; SMN2PLA2G2AMEN1KMT2ADHODH
SCHEMBL15976014 0.86 ALDH1A1 (0.38) TACR3ALDH1A1MAPTSMN1; SMN2L3MBTL1
SCHEMBL15800345 0.86 KDR (0.37) ALDH1A1MAPTL3MBTL1HPGDGAA
SCHEMBL15976015 0.86 ALDH1A1 (0.34) TACR3ALDH1A1MAPTSMN1; SMN2L3MBTL1
SCHEMBL15800330 0.85 CA12 (0.41) ALDH1A1MAPTSMN1; SMN2L3MBTL1HPGD
SCHEMBL15976018 0.84 PDCD1 (0.39) ALDH1A1MAPTSMN1; SMN2L3MBTL1MEN1
SCHEMBL15976008 0.82 KMO (0.40) ALDH1A1MAPTSMN1; SMN2L3MBTL1HPGD
SCHEMBL15800339 0.81 MAPT (0.41) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL15976012 0.76 ZAP70 (0.42) MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 TACR3 2952/4885ALDH1A1 1464/4885MAPT 4508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.